Clinical Research Directory
Browse clinical research sites, groups, and studies.
Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
Sponsor: Washington University School of Medicine
Summary
The proposed study aims to begin the multi-step process of establishing the reliability and validity of hepatic triglyceride content (HTGC) and carotid artery intima-media thickness (IMT) as biomarkers of cardiometablic risk in children treated for mental illness. The distribution of HTGC and carotid IMT-proximate indicators of cardiometabolic risk-across a range of dual-energy X-ray absorptiometry (DEXA)-measured adiposity in children treated with antipsychotic agents will be characterized in comparison to healthy, untreated, non-psychiatric controls, in order to estimate effect sizes for future studies incorporating these markers. The ability of HTGC and IMT to predict cardiometabolic risk as measured by commonly-used laboratory tests, such as fasting lipids, liver function tests, C-reactive protein and serum fibrinogen, will be assessed.
Official title: Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures
Key Details
Gender
All
Age Range
6 Years - 18 Years
Study Type
OBSERVATIONAL
Enrollment
44
Start Date
2010-01-01
Completion Date
2016-06-01
Last Updated
2026-08-20
Healthy Volunteers
Yes
Conditions
Interventions
Testing (MRS, US, DEXA, blood tests)
Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States